Andrew Combs - 31 Mar 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
EVP, Head of Chemistry
Signature
/s/ Laurent Chardonnet, as Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
31 Mar 2022
Net transactions value
+$68,157
Form type
4
Filing time
04 Apr 2022, 17:08:54 UTC
Previous filing
17 Feb 2022
Next filing
09 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise $68,157 +36,062 +13% $1.89 304,442 31 Mar 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Options Exercise $0 -36,062 -42% $0.000000 50,397 01 Apr 2022 Common Stock 36,062 $1.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
F2 The stock option vested as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.